The American College of Lifestyle Medicine and Content With Purpose launch Project Remission: A Lifestyle Medicine Approach to Type 2 Diabetes , a video series featuring short documentaries, expert interviews, and patient stories highlighting the potential of lifestyle medicine to reshape diabetes care. ST. LOUIS, March 30, 2026 /PRNewswire/ -- The American College of Lifestyle Medicine (ACLM) today announces the launch of Project Remission: A Lifestyle Medicine Approach to Type 2 Diabetes, a n

FPI achieved for first-in-class combination of IDE849 (DLL3 TOP1 ADC) and IDE161 (PARG inhibitor). IDE161 (PARG) induced accumulation of TOP1 lesions enhances the efficacy and durability of TOP1 ADCs in multiple preclinical models IDE849 Phase 1 study advancing globally to determine RP2D, including current dose evaluation at 3.5 mg/kg IV Q3W. Multiple PRs observed at 2.4 mg/kg IV Q3W expansion cohort, including 3 PRs out of 4 SCLC patients pre-treated with IMDELLTRA® Targeting IDE849 monotherapy

The foundation will host screenings in 19 states between April 13-17 MINNEAPOLIS, March 30, 2026 /PRNewswire/ -- The Head and Neck Cancer Foundation will host its annual free oral cancer screening events across the country during Head and Neck Cancer Awareness week, April 13-17, 2026. The foundation seeks to bring awareness and education around head and neck cancers and the importance of early detection. Now in its fourth year, participation in the screenings has grown to include 19 states and

STANFORD, Calif.--(BUSINESS WIRE)--For decades, physicians have treated psychiatric conditions and physical conditions like diabetes or obesity as separate problems that happened to occur in the same patient. Today, Nature Mental Health published a paper that argues this view is outdated, and that metabolic dysfunction (or the inability of the body to process the food we eat in a healthy way) is not a side effect of psychiatric illness, but actually central to it. “The research suggests metaboli

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Nuclera, the biotechnology company enabling rapid access to high-quality proteins, today announced the launch of its nanodisc panel to support screening and scale-up of G-Protein Coupled Receptors (GPCRs). Building on the eProtein Discovery™ membrane protein workflow capabilities1, the nanodisc panel allows membrane protein scientists focusing on GPCR research to identify optimal membrane environments and increase production of challenging therapeuti

LONDON and WATERTOWN, Mass., March 30, 2026 /PRNewswire/ -- ChemPartner is proud to announce the expansion of our European footprint with a new scientific hub at Discovery Park in Sandwich, Kent. Situated just one hour from London in one of the UK's premier innovation clusters, this facility marks a significant milestone in our global expansion. The new site is a dedicated center for preclinical and translational research, supporting client programs from early-stage in vitro screening to advance

Sanofi on Saturday shared more mixed efficacy results from a Phase 3 atopic dermatitis program for its anti-OX40 ligand monoclonal antibody, further eroding Wall Street’s already waning confidence in the candidate. The French pharma also revealed that one more patient treated with amlitelimab developed Kaposi’s sarcoma, a type of vascular tumor, bringing the total to two cases across the drug’s development history. Sanofi tested amlitelimab in three Phase 3 trials known as COAST 1, COAST 2 and S

Partnership combines Lunit's platform-agnostic AI pathology algorithms with CellCarta's global CDx development and laboratory execution to help biopharma teams de-risk assets and accelerate evidence generation and CDx launch pathways. SEOUL, South Korea and MONTREAL, March 30, 2026 /PRNewswire/ -- Lunit (KRX: 328130), a leading provider of AI for cancer diagnostics and precision oncology, and CellCarta, a leading global contract research organization (CRO) laboratory to the biopharmaceutical ind

STOCKHOLM, March 30, 2026 /PRNewswire/ -- Sobi® (STO: SOBI) today announced that the European Medicines Agency (EMA) has validated an indication extension application for Tryngolza® (olezarsen) for the treatment of adult patients with severe hypertriglyceridemia (sHTG) ≥880 mg/dL (≥10 mmol/L). Patients with elevated triglyceride levels have substantially higher risks of all-cause mortality, atherosclerotic cardiovascular events, and acute pancreatitis[1]. The submission is supported by results f

In a separate announcement made today, the Company also secured A$83 million in private placement funding to support growth initiatives, including European expansion. MELBOURNE, Australia, March 30, 2026 /PRNewswire/ -- 4DMedical Limited (ASX:4DX), the global leader in cardiothoracic imaging software, announces that its latest imaging technology, CT:VQ™ has received CE Mark certification for commercial use in the European Union. 4DMedical will quickly launch commercial deployment of CT:VQ acro